Clinical trials: PAOD (Peripheral Arterial Obstructive Disease)
- Condition PAOD (Peripheral Arterial Obstructive Disease)
- Funder type Industry (pharma, biotech, devices)
Peripheral Arterial Occlusive Disease
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients…
- Trial name
- ESPECIAL (NCT00596752)
- Testing
- Alprostadil
- Where
- 78 sites in Czechia, Germany and 4 more
- Volunteers
- 840 people
- Sponsor
- UCB BIOSCIENCES GmbH
Peripheral Arterial Occlusive Disease
Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation
The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single doses of NV1FGF.
- Trial name
- NCT01157143
- Testing
- XRP0038 (NV1FGF)
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 6 people
- Sponsor
- Sanofi
Peripheral Arterial Disease, Stenotic Femoro-popliteal Arteries
Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease
The purpose of this study is to determine plasma levels of paclitaxel and catheter tolerability subsequent to treating patients with peripheral arterial occlusive disease (PAOD) with paclitaxel-coated balloon catheters.
- Conditions
- Peripheral Arterial Disease, Stenotic Femoro-popliteal Arteries, Occluded Femoro-popliteal Arteries, Atherosclerosis
- Trial name
- NCT01007578
- Testing
- Paclitaxel-coated balloon catheter angioplasty
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Bayer
Peripheral Arterial Occlusive Disease
Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one…
- Trial name
- NCT03339973
- Testing
- allo-APZ2-PAOD
- Where
- 18 sites in Austria, Czechia and 3 more
- Volunteers
- 24 people
- Sponsor
- RHEACELL GmbH & Co. KG
Periferal Arterial Occlusive Disease, PAOD
Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg
A study to assess the effect of negative pulsating pressure therapy on patients with impaired blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase the blood flow to the leg in these patients.
- Trial name
- NCT01893840
- Testing
- FlowOx
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Otivio AS
Critical Limb Ischemia
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
Critical Limb Ischemia prevents the legs and feet from receiving oxygen and nutrients needed for proper function. This severe lack of blood flow can lead to painful legs while walking or at rest and can result in foot sores…
- Trial name
- NCT01245335
- Testing
- BMAC injection
- Where
- 34 sites in United States
- Volunteers
- 97 people
- Sponsor
- Harvest Technologies
Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD
Prostaglandin E1 in Outpatients With Intermittent Claudication
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with…
- Trial name
- NCT01263925
- Testing
- Alprostadil (Prostaglandin E1), Pentoxifylline
- Where
- 36 sites in Germany
- Volunteers
- 561 people
- Sponsor
- UCB Pharma
Peripheral Arterial Obstructive Disease
Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone
A randomized Multicentric open-label controlled trial. The primary objective of the study is to assess the improvement of endothelial function under sulodexide + conventional treatment or conventional treatment alone in patients…
- Trial name
- AWAOMI2 (NCT03370705)
- Testing
- Sulodexide, Statin, Antiplatelet Agents
- Where
- 3 sites in Tunisia
- Volunteers
- 156 people
- Sponsor
- Alfa Wassermann Tunisia
Peripheral Arterial Occlusive Disease (PAOD)
Evaluation of FUSION™ Vascular Graft for Above Knee Targets
The purpose of the post-market study was to evaluate the safety and performance of the FUSION Vascular Graft.
- Trial name
- PERFECTION (NCT01601496)
- Testing
- FUSION Vascular Graft
- Where
- 10 sites in Austria, Germany
- Volunteers
- 117 people
- Sponsor
- Maquet Cardiovascular
Peripheral Arterial Disease
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive…
- Trial name
- TALISMAN 201 (NCT00368797)
- Testing
- XRP0038 (NV1FGF)
- Where
- 6 sites in Belgium, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
Chronic Total Occlusion of Artery of the Extremities
Crosser Enters The Right Arterial Lumen
The purpose of this study is to determine if the CROSSER CTO Recanalization System can facilitate the successful crossing of Chronic Total Occlusions in the Central lumen of the Superficial Femoral Artery (SFA).
- Trial name
- CENTRAL (NCT01205386)
- Testing
- 1. CROSSER System
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
CLTI Defined as Rutherford Category 4 or 5, PAOD (Peripheral Arterial Obstructive Disease)
Resoloy Initial Safety Evaluation
The aim of this clinical trial is to learn if the resorbable scaffold can be successfully implanted in below-the-knee arteries and help to restore the blood flow in diseased vessels.
- Trial name
- RISE (NCT07648017)
- Testing
- PTA
- Where
- Uzbekistan
- Volunteers
- 10 people
- Sponsor
- MeKo Manufacturing e.K.
Severe Peripheral Artery Occlusive Disease
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Peripheral Arterial Occlusive Disease (PAOD) is a condition caused by ischemia in the legs due to atherosclerotic disease affecting the larger arteries of the legs.
- Trial name
- TALISMAN202 (NCT00798005)
- Testing
- XRP0038 (NV1FGF)
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sanofi
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac…
- Trial name
- MOBILITY OE (NCT01396525)
- Testing
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Abbott Medical Devices
Atherosclerosis, Peripheral Artery Disease
The ABSORB BTK (Below The Knee) Clinical Investigation
The purpose of the ABSORB BTK Clinical Investigation is to evaluate the safety and efficacy of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) in subjects with critical limb ischemia (CLI) following…
- Conditions
- Atherosclerosis, Peripheral Artery Disease, Peripheral Vascular Disease, PAD
- Trial name
- NCT01341340
- Testing
- Everolimus Eluting BVS
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- Abbott Medical Devices
Intermittent Claudication
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction.
- Trial name
- NCT01256775
- Testing
- NCX-4016
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- NicOx Research Institute S.r.l.
Peripheral Arterial Occlusive Disease
Isovue in Peripheral Digital Subtraction Angiography (DSA)
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
- Trial name
- NCT01075217
- Testing
- iopamidol, iodixanol
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Bracco Diagnostics, Inc
Peripheral Arterial Occlusive Disease, Critical Limb Ischemia
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of [89Zr]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers.
- Trial name
- CHASE (NCT06204237)
- Testing
- [89Zr]Zr-DFO-APAC, PET/CT scan
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aplagon Oy
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.
To determine the safety and efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac artery.
- Trial name
- MOBILITY AP (NCT00844532)
- Testing
- Absolute Pro™ Peripheral Self-Expanding Stent System
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Abbott Medical Devices
PAOD - Peripheral Arterial Occlusive Disease, PAD
Recombinant SeV-hFGF2/dF Injection for PAOD
Lower extremity arteriosclerosis obliterans is due to the formation of atherosclerotic plaque in the lower extremities, resulting in the stenosis and occlusion of the artery, leading to chronic ischemia of the limbs.
- Conditions
- PAOD - Peripheral Arterial Occlusive Disease, PAD, Critical Limb Ischemia
- Trial name
- NCT03668353
- Testing
- Recombinant SeV-hFGF2/dF Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.